WHO Issues First-Ever Guidelines for GLP-1 Obesity Drugs as Global Rates Hit One Billion

The World Health Organization has released its first formal recommendations on using GLP-1–based medications for obesity, marking a major shift in global public-health strategy amid...

The World Health Organization has released its first formal recommendations on using GLP-1–based medications for obesity, marking a major shift in global public-health strategy amid rapidly rising obesity rates.

Key Takeaway

More than one billion people worldwide are now living with obesity, prompting the WHO to publish its first guidance on the use of GLP-1 therapies—popular drugs such as semaglutide, liraglutide, and tirzepatide. While the medications show strong potential for long-term weight management, the WHO stresses that they must be paired with lifestyle interventions and broader public-health reforms.

A Growing Global Health Crisis

Obesity has become one of the most urgent health challenges of the 21st century. According to recent WHO estimates, the condition was linked to 3.7 million deaths in 2024 alone. Factors such as rapid urbanisation, widespread availability of calorie-dense foods, rising stress levels, and increasingly sedentary lifestyles have accelerated the problem across both developed and developing nations.

Health experts warn that uncontrolled obesity significantly raises the risk of type-2 diabetes, heart disease, stroke, and several cancers—placing enormous strain on healthcare systems worldwide.

What Are GLP-1 Therapies and Why Are They Important?

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone that helps regulate blood sugar levels and appetite. GLP-1 receptor agonists—drugs designed to mimic the hormone’s effects—have rapidly transformed obesity and diabetes management.

These medications:

Reduce hunger by slowing digestion
Promote fullness
Support sustained calorie reduction
Improve glucose control in people with type-2 diabetes

The WHO added several GLP-1 drugs to its Essential Medicines List in 2025 for high-risk diabetes patients. The new guideline extends their use to obesity treatment, though with caution.

WHO’s New Guidance: Conditional, but Significant

The WHO’s first guideline on obesity treatment with GLP-1 medications outlines two key recommendations:

1. GLP-1 therapies may be used for long-term obesity management in adults (excluding pregnant women).

The recommendation is conditional. The WHO acknowledges strong evidence for weight loss and metabolic improvements but cites several concerns:

Limited long-term safety data
High cost
Uneven availability worldwide
Uncertainty around weight regain after discontinuation
Health-system challenges in prescribing and monitoring these drugs

2. Medication must be paired with structured behavioural programs.

The WHO insists that patients receiving GLP-1 therapies should also be offered intensive lifestyle interventions—including personalised nutrition advice, structured exercise programs, and ongoing support from health professionals.

“Medicines Alone Won’t Solve Obesity” — WHO Chief

WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasised that obesity should be treated as a chronic disease requiring lifelong care. He noted that GLP-1 drugs are promising tools but cannot replace broader efforts to promote healthier environments.

The organisation is urging countries to:

Create healthier food environments, such as regulating marketing of unhealthy foods and improving access to affordable nutritious options.
Identify people at risk early through routine screening and primary care outreach.
Ensure access to equitable, person-centred treatment, including counselling, nutritional therapy, and long-term monitoring.

A Supply Challenge Ahead

Despite growing demand, the WHO warns that global manufacturing capacity may fall far short of need. Even with rapid production expansion, fewer than 10% of eligible individuals may be able to access GLP-1 therapies by 2030.

Experts note that without coordinated policy efforts—such as price controls, generic development, and technology-sharing agreements—these drugs risk becoming accessible only to wealthy populations, widening health inequality.

Why This Guidance Matters

This is the first time the WHO has formally recognised pharmacological treatment as part of a global obesity strategy. The move signals:

Increasing acceptance of obesity as a chronic medical condition rather than a lifestyle issue.
A push for evidence-based treatment frameworks for countries developing national obesity plans.
Recognition of emerging drug technologies that could reshape metabolic health in coming decades.

However, the agency underscores that lifestyle changes, community support systems, and public-health reforms remain the backbone of effective, long-term obesity prevention.